Acadian Asset Management
BMRN icon

Acadian Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Acadian Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.73M Sell
30,291
-8,065
-21% -$442K ﹤0.01% 1109
2026
Q1 		$2.16M Sell
38,356
-137,586
-78% -$8.02M ﹤0.01% 934
2025
Q4 		$10.4M Sell
175,942
-106,578
-38% -$5.8M 0.02% 473
2025
Q3 		$15.3M Buy
282,520
+189,920
+205% +$10.9M 0.03% 381
2025
Q2 		$5.08M Buy
92,600
+68,589
+286% +$4.04M 0.01% 581
2025
Q1 		$1.7M Sell
24,011
-6,889
-22% -$463K ﹤0.01% 801
2024
Q4 		$2.03M Buy
30,900
+18,170
+143% +$1.22M 0.01% 761
2024
Q3 		$892K Buy
12,730
+617
+5% +$51.6K ﹤0.01% 939
2024
Q2 		$994K Buy
12,113
+9,576
+377% +$797K ﹤0.01% 992
2024
Q1 		$221K Buy
2,537
+625
+33% +$56K ﹤0.01% 1169
2023
Q4 		$184K Sell
1,912
-1,770
-48% -$157K ﹤0.01% 1247
2023
Q3 		$325K Buy
3,682
+1,660
+82% +$148K ﹤0.01% 1104
2023
Q2 		$175K Buy
+2,022
New +$190K ﹤0.01% 1298
2022
Q3 		– Sell
-12,060
Closed -$1M – 1677
2022
Q2 		$1M Buy
12,060
+11,629
+2,698% +$926K 0.01% 817
2022
Q1 		$32K Buy
431
+344
+395% +$28.8K ﹤0.01% 1514
2021
Q4 		$7K Sell
87
-321,579
-100% -$26.5M ﹤0.01% 1642
2021
Q3 		$24.8M Buy
321,666
+285,148
+781% +$22.5M 0.09% 184
2021
Q2 		$3.05M Buy
36,518
+17,527
+92% +$1.39M 0.01% 597
2021
Q1 		$1.43M Sell
18,991
-24,346
-56% -$1.99M 0.01% 839
2020
Q4 		$3.8M Buy
43,337
+19,677
+83% +$1.56M 0.01% 579
2020
Q3 		$1.8M Buy
23,660
+3,082
+15% +$312K 0.01% 699
2020
Q2 		$2.54M Buy
20,578
+19,596
+1,996% +$1.95M 0.01% 673
2020
Q1 		$83K Buy
+982
New +$84.6K ﹤0.01% 1387

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Acadian Asset Management's BMRN Position: Q2 2026 in Review

Acadian Asset Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 21% in Q2 2026, selling an estimated $442K and leaving 30,291 shares worth $1.73M. The position accounts for ﹤0.01% of the portfolio, ranked #1109.

Acadian Asset Management first reported a position in BMRN in Q1 2020 and has held it in 23 quarters since. The position peaked at $24.8M in Q3 2021. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Acadian Asset Management held 30,291 shares of BioMarin Pharmaceuticals worth $1.73M as of Q2 2026.
  • Acadian Asset Management sold 8,065 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $442K.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1109 holding.
  • Acadian Asset Management first reported a position in BioMarin Pharmaceuticals in Q1 2020 and has held it in 23 quarters since.
  • Acadian Asset Management's BioMarin Pharmaceuticals position peaked at $24.8M in Q3 2021.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.